UPDATE 2-U.S. FDA approves MannKind's diabetes therapy Afrezza

June 27, 2014 9:07 PM

20 0

WASHINGTON, June 27 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann.

Afrezza is a form of insulin delivered using a whistle-sized inhaler. It acts more rapidly than traditional injected insulin sold by Eli Lilly and Co and Denmark's Novo Nordisk .

Read more

To category page